Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06406114 · ClinicalTrials.gov registry record · Phase 2
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
A Phase 2 study of Antibiotic Allergy and Drug Hypersensitivity, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 6
- Study locations
NCT06406114 is a Phase 2 study of Antibiotic Allergy and Drug Hypersensitivity that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 300 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT06406114, a Phase 2 study of Antibiotic Allergy and Drug Hypersensitivity, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 6
- Study locations
Study Summary
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
Conditions Studied
Interventions
- DRUG Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing
- DRUG Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge
- DRUG Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge
- DRUG Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge
- DRUG Amoxicillin double-blind placebo-controlled drug challenge
Study Locations (6)
Arizona
- Mayo Clinic Arizona - Scottsdale
California
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Rochester General Hospital - Rochester
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06406114
The ClinicalTrials.gov registry entry for NCT06406114 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Antibiotic Allergy appearing as the primary indexed condition, and to 5 interventions - of which Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing is the first listed.
NCT06406114 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06406114 about?
NCT06406114 is a clinical study titled "Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing". Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin ...
What is the current status of trial NCT06406114?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-05-05. Estimated completion is 2028-12-31.
What conditions does trial NCT06406114 study?
This clinical trial studies the following conditions: Antibiotic Allergy, Drug Hypersensitivity, Drug Allergy, Cephalosporin Allergy, Beta Lactam Adverse Reaction.
What interventions are being tested in trial NCT06406114?
The interventions under investigation include: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing (DRUG), Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge (DRUG), Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge (DRUG), Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge (DRUG), Amoxicillin double-blind placebo-controlled drug challenge (DRUG).
Who is sponsoring clinical trial NCT06406114?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06406114 being conducted?
This trial has 6 study locations across Arizona, California, Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antibiotic Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.